Arsenic induces decreased expression of β2-adrenergic receptors in cultured keratinocytes

Archives of Dermatological Research

Volumn 290, Issue 7, 1998, Pages 402-404

  Chang, Huoy Rou ^a   Yu, Hsin Su ^b   Chai, Chee Yin ^b   Lin, Ying Rong ^b   Yu, Chia Li ^c  

^a Chin Nan Coll of Pharm and Science   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

2 adrenergic receptors; Arsenic; Keratinocytes

Indexed keywords

ADENYLATE CYCLASE; ARSENIC; BETA 2 ADRENERGIC RECEPTOR; CYANOPINDOLOL I 125; CYCLIC AMP;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; EPIDERMIS; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR DENSITY; SKIN CANCER;

ADULT; ARSENIC; CELLS, CULTURED; DOWN-REGULATION; HUMANS; IODINE RADIOISOTOPES; IODOCYANOPINDOLOL; KERATINOCYTES; MALE; POISONS; PROTEIN BINDING; RECEPTORS, ADRENERGIC, BETA-2;

EID: 0031660107     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004030050325     Document Type: Article

References (20)

1. Chappell WR (1997) Arsenic: exposure and health effects. In: Guo HR (eds) Arsenic in drinking-water and skin cancer. Chapman & Hall. London, pp 243-259
2. Collins S, Caron MG, Lefkowitz RJ (1992) From ligand binding to gene expression: new insights into the regulation of G-protein-coupled receptors. Trends Biol Sci 17:37-39
3. Schallreuter KU, Lemke KR, Pittelkow MR, Wood JM, Korner C, Malik R (1995) Catecholamine in human keratinocyte differentiation. J Invest Dermatol 104:953-957
4. Steinkraus V, Steintath M, Stove L, Korner C, Abeck D, Mensing H (1993) β-adrenergic receptors in psoriasis. Evidence for down-regulation in lesional skin. Arch Dermatol Res 285:300-304
5. Steinkraus V, Steinfath M, Korner C, Mensing H (1992) Binding of beta-adrenergic receptors in human skin. J Invest Dermatol 98:475-480
6. Scatchard G (1949) The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51:660-672
7. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
8. Schallreuter KU, Wood JM, Lemke R, LePoole C, Das P, Westerhof W, Pittelkow MR, Thody AJ (1992) Production of catecholamines in the human epidermis. Biochem Biophys Res Commun 189:72-78
9. Iizuka H, Adachi H, Halprin KM, Levine V (1976) Histamine (H2) receptor-adenylate cyclase system in pig skin (epidermis). Biochim Biophys Acta 437:150-157
10. Adachi K, Iizuka H, Halprin KM, Levine V (1977) Specific refractoriness of adenylate cyclase to epinephrine, prostaglandin E, histamine and AMP. Biochim Biophys Acta 497:428-436
11. Duell EA (1980) Adenosine-induced alterations in the adenosine 3′,5′-monophosphate levels in mammalian epidermis. Mol Pharmacol 18:49-52
12. Adachi K, Yoshikawa K, Halprin KM, Levine M (1975) Prostaglandins and cyclic AMP in epidermis. Br J Dermatol 92:381-388
13. Harris RR, Mackenzie IC (1981) The effects of α- and β-adrenergic agonists and cyclic adenosine 3′,5′-monophosphate on epidermal metabolism. J Invest Dermatol 77:337-340
14. Voorhees JJ, Duell EA (1971) Psoriasis as a possible defect of the adenyl cyclase-cyclic AMP cascade. Arch Dermatol 104: 352-358
15. Iizuka H, Matsuo S, Tamura T, Ohkuma N (1988) Increased cholera toxin-, and forskolin-induced cyclic AMP accumulations in psoriatic involved versus uninvolved or normal human epidermis. J Invest Dermatol 91:154-157
16. Steinkraus V, Steinfath M, Mensing H (1992) β-adrenergic blocking drugs and psoriasis. J Am Acad Dermatol 27:266-267
17. Citri Y, Schramm M (1980) Resolution, reconstitution and kinetics of the primary action of a hormone receptor. Nature 278:291-300
18. Gilman AG (1984) G proteins and dual control of adenylate cyclase. Cell 36:577-579
19. Garte SJ, Belman S (1980) Tumour promoter uncouples beta-adrenergic receptor from adenylate cyclase in mouse epidermis. Nature 284:171-173
20. Chang HR, Chen SS, Chen TJ, Ho CK, Chang HC, Yu HS (1996) Lymphocyte β adrenergic receptors and plasma catecholamine levels in lead-exposed workers. Toxicol Appl Pharmacol 138:1-5